Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders

International Journal of Hematology

Volumn 65, Issue 2, 1997, Pages 123-128

  Kawatani, Toshio ^a   Endo, Akira ^a   Tajima, Fumihito ^a   Ooi, Shinji ^b   Kawasaki, Hironaka ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b MATSUE RED CROSS HOSPITAL   (Japan)

Author keywords

Chronic myeloproliferative disorders; Soluble interleukin 2 receptor

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LEUKOCYTE COUNT; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL;

EID: 0031081350     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(96)00554-3     Document Type: Article

References (17)

1. [1] Yasuda N, Lai PK, Ip SH, et al. Soluble interleukin 2 reseptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 1988;71:1021-1026.
2. [2] Kay NE, Burton J, Wagner D, Nelson DL. The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors. Blood 1988;72:447-452.
3. [3] Kalmanti M, Karamolengou K, Dimitriou H, et al. Serum levels of tumor necrosis factor and soluble interleukin-2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma. Int J Hematol 1993;57:147-152.
4. [4] Cimino G, Amadori S, Cava MC, et al. Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients. Leukemia 1991;5:32-35.
5. [5] Motoi T, Uchiyama T, Hori T, Itoh K, Uchino H, Ueda R. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood 1989;74:1052-1057.
6. [6] Wang JC, Wang A. Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis. Br J Haematol 1994;86:380-382.
7. [7] Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the polycythemia vera study group. Semin Hematol 1986;23:177-182.
8. [8] Wasserman LR. The management of polycythemia vera. Br J Haematol 1971;21:371-376.
9. [9] Speck B, Bortin MM, Champlin R, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1984;i:665-668.
10. [10] Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, and Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987;69:1280-1288.
11. [11] Visani G, Delwel R, Touw I, Bot F, Löwenberg B. Membrane receptors for interleukin 2 on hematopoietic precursors in chronic myeloid leukemia. Blood 1987;69:1182-1187.
12. [12] Allan NC, Richards SM, Shepherd PCA, on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995;345:1392-1397.
13. [13] Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia. Bone Marrow Transplant 1989;4:63.
14. [14] The Italian Cooperative Study Group on Chronic Myeloid Leukemia. A prospective comparison of α-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematology 1992;77:204-214.
15. [15] Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
16. [16] Kantargian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995;122:254-261.
17. [17] The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Eugl J Med 1994;330:820-825.